Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial
mediaposted on 2021-05-26, 10:56 authored by Adis journals on behalf of, Fernando J. Martinez, Amna Sadaf Afzal, Jaclyn A. Smith, Anthony P. Ford, Jerry Jing Li, Yuping Li, Michael Kittelberger
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.